Strongbridge Biopharma PLC believes the robust efficacy and safety – particularly in the liver – of its Recorlev (levoketoconazole) support a first-line role in Cushing's syndrome, a rare endocrinologic condition marked by excess cortisol.
Strongbridge (formerly called Cortendo) announced positive results from the Phase III pivotal SONICS study of Recorlev for endogenous Cushing's syndrome...






